Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an update.
Hangzhou Tigermed Consulting has released its unaudited first quarterly report for the 2026 financial year, prepared under China Accounting Standards for Business Enterprises. The document, published in both Chinese and English with the Chinese version prevailing in case of discrepancies, outlines the group’s early-year financial performance for shareholders and public investors.
The company emphasizes that the figures have not been audited, signaling that results may be subject to adjustments as the year progresses and as full reviews are completed. The disclosure, made under Hong Kong listing and securities regulations, reflects Tigermed’s ongoing compliance with transparency requirements and provides stakeholders with preliminary insight into its 2026 operating trajectory.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a People’s Republic of China-incorporated company listed in Hong Kong that operates in the pharmaceutical and biotechnology services sector. The group provides clinical research and related consulting services, supporting drug development for clients in healthcare and life sciences markets.
Average Trading Volume: 1,815,434
Technical Sentiment Signal: Sell
Current Market Cap: HK$48.3B
For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.